ISRCTN67038373已完成2 期
Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)
niversity of Nottingham0 个研究点目标入组 54 人开始时间: 2018年10月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33172941/ Peer reviewed protocol article (added 11/08/2022) 2023 Results article in https://doi.org/10.1016/S1474-4422(23)00157-6 (added 22/06/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 12/02/2020:
- •1. Aged >18 years
- •2. Confirmed intracerebral hemorrhage on imaging
- •3. Less than 24 hours from onset of symptoms (or from when last seen healthy)
- •4. Prescribed and thought to be taking a daily oral antiplatelet drug in the preceding seven days (cyclooxygenase inhibitors, phosphodiesterase inhibitors or P2Y12 inhibitors)
- •5. Signed consent (patient/personal/professional representative)
- •Previous participant inclusion criteria:
- •1. Adults (>17 years)
- •2. Confirmed intracerebral haemorrhage on imaging
- •3. Less than 12 hours from onset of symptoms [or from when last seen healthy]
- •4. Prescribed and thought to be taking a daily oral antiplatelet drug in the preceding seven days (cyclooxygenase inhibitors, phosphodiesterase inhibitors or P2Y12 inhibitors)
- •5. Signed consent (patient/personal/professional representative)
排除标准
- •1. Aneurysmal subarachnoid haemorrhage known at time of enrolment
- •2. Haemorrhage known to be due to transformation of infarction
- •3. Haemorrhage known to be due to thrombolytic drug
- •4. Haemorrhage known to be due to venous thrombosis
- •5. Risk/s of fluid retention associated with desmopressin judged clinically significant by the attending physician (for example patients with pulmonary oedema and/or cardiac failure)
- •6. Significant hypotension (systolic blood pressure < 90mmHg)
- •7. Known drug-eluting coronary artery stent in previous three months
- •8. Allergy to desmopressin
- •9. Pregnant or breastfeeding
- •10. Life expectancy less than four hours, or planned for palliative care only
- •11. Glasgow coma scale less than 5
- •12. mRS > 4
- •13. Participation in another concurrent drug trial
研究者
相似试验
进行中（未招募）
1 期
A trial to assess whether desmopressin could reduce risk of death or disability for patients with intracerebral haemorrhage (bleeding into the brain) taking antiplatelet (blood thinning ) drugs. study will be modified Rankin scale at day 90 (shift analysis).Intracerebral haemorrhageMedDRA version: 21.1 Level: PT Classification code 10019016 Term: Haemorrhagic stroke System Organ Class: 10029205 - Nervous system disordersEUCTR2018-001904-12-GBniversity of Nottingham50
已完成
2 期
Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to HaemorrhageStroke, AcuteNCT03696121University of Nottingham54
Unknown
4 期
Desmopressin for Bleeding Related to Low Body TemperatureHypothermia Induced Impairment of Primary HaemostasisNCT00902057The University of Hong Kong48
Unknown
4 期
Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve SurgeryBlood Coagulation DisordersC.Surgical Procedure CardiacNCT03343418Instituto do Coracao108
已完成
2 期
The evaluation efficacy of Desmopressin in improvement coagulation status of patients with combined factor V and VIII deficiency.IRCT2015020120894N1Vice chancellor for research, Mashhad University of Medical Sciences24